Intellia Therapeutics Company Profile (NASDAQ:NTLA)

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its earnings results on Thursday, August, 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.04. The firm had revenue of $5.90 million for the quarter, compared to analysts' expectations of $5.83 million. Intellia Therapeutics had a negative return on equity of 22.70% and a negative net margin of 204.48%. The company's quarterly revenue was up 40.5% on a year-over-year basis. View Intellia Therapeutics' Earnings History.

8 brokers have issued 1 year price objectives for Intellia Therapeutics' shares. Their forecasts range from $20.00 to $36.00. On average, they expect Intellia Therapeutics' stock price to reach $26.80 in the next year. View Analyst Ratings for Intellia Therapeutics.

Here are some recent quotes from research analysts about Intellia Therapeutics stock:

• 1. Cann analysts commented, "Loss per share was $0.45 compared to our estimated loss of $0.39. This was the result of lower than expected Collaborative revenue of $5.9 million compared to our estimate of $6.5 million and higher than estimated R&D expenses of $15.6 million compared to our estimated $14.1 million. Lower revenue and higher expenses were partially offset by a higher than estimated shares outstanding. There were no other meaningful variances in the quarter. Our outlook remains basically unchanged. We have made modest adjustments to our estimated shares outstanding and R&D expense." (8/1/2017)
• 2. According to Zacks Investment Research, "Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (4/18/2017)
• 3. Chardan Capital analysts commented, "We initiate coverage of Intellia Therapeutics (NTLA) with a Buy rating (PT $19), on our view of possible downside driven by the company's IP weakness overridden by relative under-valuation of the CRISPR sector. Intellia is a preclinical biotech company aiming to treat various genetic conditions using the CRISPR-Cas9 gene editing system, in which a CRISPR guide RNA (gRNA) targets a Cas9 nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Intellia's lead asset for transthyretin (TTR) amyloidosis, partnered with Neutral-rated Regeneron Pharmaceuticals, is guided to initiate IND-enabling studies by 2H17/1H18." (3/27/2017)

Some companies that are related to Intellia Therapeutics include Medpace Holdings (MEDP), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Global Blood Therapeutics (GBT), Momenta Pharmaceuticals (MNTA), Genus plc (GNS), Immunomedics (IMMU), Genomic Health (GHDX), Esperion Therapeutics (ESPR), Albany Molecular Research (AMRI), Cellectis S.A. (CLLS), BeyondSpring (BYSI), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Crispr Theraptc (CRSP), Spectrum Pharmaceuticals (SPPI), Enanta Pharmaceuticals (ENTA), TG Therapeutics (TGTX) and ImmunoGen (IMGN).

Intellia Therapeutics' management team includes the folowing people:

• Perry A. Karsen, Chairman of the Board
• Nessan Bermingham, President, Chief Executive Officer, Founder, Director
• Graeme Bell, Chief Financial Officer, Executive Vice President
• Jose E. Rivera J.D., Executive Vice President, General Counsel
• John M. Leonard M.D., Executive Vice President - Research and Development
• Frank Verwiel M.D., Director
• Caroline D. Dorsa, Independent Director
• Jean-Francois Formela M.D., Independent Director
• Carl L. Gordon Ph.D., Independent Director

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Atlas Venture Associates IX LLC (10.35%), FMR LLC (8.94%), Vanguard Group Inc. (2.76%), Artal Group S.A. (0.69%), ARK Investment Management LLC (0.48%) and State Street Corp (0.46%). Company insiders that own Intellia Therapeutics stock include Bros Advisors Lp Baker, Carl L Gordon, Institutes For Biomed Novartis, Jean Francois Formela and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Intellia Therapeutics.

Intellia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Tekla Capital Management LLC, Northern Trust Corp, Acadian Asset Management LLC and ProShare Advisors LLC. Company insiders that have sold Intellia Therapeutics stock in the last year include Jean Francois Formela and Venture Fund Ix LP Atlas. View Insider Buying and Selling for Intellia Therapeutics.

Intellia Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Vanguard Group Inc., OxFORD Asset Management LLP, GSA Capital Partners LLP, State Street Corp, TIAA CREF Investment Management LLC, Dimensional Fund Advisors LP and American Century Companies Inc.. Company insiders that have bought Intellia Therapeutics stock in the last two years include Bros Advisors Lp Baker, Carl L Gordon and Institutes For Biomed Novartis. View Insider Buying and Selling for Intellia Therapeutics.

Shares of Intellia Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Intellia Therapeutics stock can currently be purchased for approximately $17.43.